CliffBio
small molecule

ADHANSIA XR

METHYLPHENIDATE HYDROCHLORIDE

Loss of exclusivityNovember 2038latest FDA-listed patent expiry
CompanyKNOA →See this company's full patent-cliff portfolio

Drug detail

Brand nameADHANSIA XR
Active ingredientMETHYLPHENIDATE HYDROCHLORIDE
Strength55MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
10722473November 2038use U-2357
10512613October 2035use U-2357
10449159October 2035use U-2357
10500162October 2035use U-2357
10568841October 2035product
10111839October 2035use U-2357
10507186October 2035product
9974752October 2035product
10292938October 2035product
10688060October 2035product
10292939October 2035product
10512612October 2035product

More from KNOA

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ADHANSIA XR patent cliff — loss of exclusivity November 2038 | CliffBio